Fundamentals of Pharmacology and Applications in Pharmacogenetics

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 485-497

  Al Ghoul, Mohammad ^a   Valdes Jr , Roland ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450; CYTOCHROME P450 2D6; TAMOXIFEN; UNSPECIFIC MONOOXYGENASE;

CATALYST; CLINICAL LABORATORY; CLINICAL MEDICINE; DNA POLYMORPHISM; DRUG METABOLISM; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; OXIDATION; PATIENT CARE; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CLINICAL LABORATORY TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 57049100974     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.07.001     Document Type: Review

References (28)

1. Linder M.W., and Valdes Jr. R. Fundamentals of pharmacogenetics. In: Wong S.H.Y., Linder M.W., and Valdes Jr. R. (Eds). Pharmacogenomics and proteomics: enabling the practice of personalized medicine (2006), AACC Press 13-19
2. Weber W. Human drug response. In: Bobrow M., Harper P.S., Scriver C., et al. (Eds). Pharmacogenetics (1997), Oxford University Press, New York 21-40
3. Valdes R Jr, Payne D, Linder M, et al. Guidelines and recommendations for laboratory analysis and application of pharmacogenetics in clinical practice. Available at: http://www.aacc.org/members/nacb/LMPG/OnlineGuide/DraftGuidelines/Pharmacogenetics/Pages/default.aspx. National Academy of Clinical Biochemistry 2007, in press.
4. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 21 (2005) 2211-2221
5. de Leon J., Armstrong S.C., and Cozza K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47 1 (2006) 75-85
6. Feigelson H.S., McKean-Cowdin R., Coetzee G.A., et al. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61 2 (2001) 785-789
7. Linder M.W., and Valdes Jr. R. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 25 5 (2001) 405-413
8. Nelson D.R., Kamataki T., Waxman D.J., et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12 1 (1993) 1-51
9. Phillips K.A., and Van Bebber S.L. Measuring the value of pharmacogenomics. Nat Rev Drug Discov 4 6 (2005) 500-509
10. Tuckson R.V. Realizing the promise of pharmacogenomics: opportunities and challenges. Biotechnology Law Report 26 3 (2007) 261-291
11. Johnson J.A., and Cavallari L.H. Cardiovascular pharmacogenomics. Exp Physiol 90 3 (2005) 283-289
12. Johnson J.A., and Humma L.M. Pharmacogenetics of cardiovascular drugs. Brief Funct Genomic Proteomic 1 1 (2002) 66-79
13. Agundez J.A., Gallardo L., Ledesma M.C., et al. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 61 1 (2001) 59-63
14. Gerstein M.B., Bruce C., Rozowsky J.S., et al. What is a gene, post-ENCODE? History and updated definition. Genome Res 17 6 (2007) 669-681
15. Khoury M.J. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 5 4 (2003) 261-268
16. Sikka R., Magauran B., Ulrich A., et al. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med 12 12 (2005) 1227-1235
17. Weinshilboum R., and Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3 9 (2004) 739-748
18. Linder M.W., and Valdes Jr. R. Fundamentals and applications of pharmacogenetics for the clinical laboratory. Ann Clin Lab Sci 29 2 (1999) 140-149
19. Linder M.W., Prough R.A., and Valdes Jr. R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43 2 (1997) 254-266
20. Hopkins M.M., Ibarreta D., Gaisser S., et al. Putting pharmacogenetics into practice. Nat Biotechnol 24 4 (2006) 403-410
21. Schmedders M., van Aken J., Feuerstein G., et al. Individualized pharmacogenetic therapy: a critical analysis. Community Genet 6 2 (2003) 114-119
22. Goetz M.P., Kamal A., and Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83 1 (2008) 160-166
23. Goodman T., Ferro A., and Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66 2 (2008) 222-232
24. Linder M.W., and Valdes Jr. R. Pharmacogenetics in the practice of laboratory medicine. Mol Diagn 4 4 (1999) 365-379
25. Linder M.W., Looney S., Adams III J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 14 3 (2002) 227-232
26. Valdes Jr. R., and Linder M.W. Fine-tuning pharmacogenetics: paradigm for linking laboratory results to clinical action. Clin Chem 50 9 (2004) 1498-1499
27. Valdes Jr. R., Linder M.W., and Jortani S.A. What is next in pharmacogenomics? Translating it to clinical practice. Pharmacogenomics 4 4 (2003) 499-505
28. Linder M.W., and Valdes Jr. R. Pharmacogenetics: fundamentals and applications. Therapeutic drug monitoring and toxicology. Washington (DC):AACC 20 1 (1999) 9-17